Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003, Tislelizumab, and Capecitabine in Locally Recurrent Nasopharyngeal Carcinoma
NCT07331428Phase 2
Key facts
- Status
- Recruiting
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Fujian Medical University Cancer Hospital
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Drugs
- becotatug vedotin
- Conditions
- nasopharyngeal carcinoma (NPC)
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate. Started Jun 2026; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
MRG003 + Tislelizumab -> Capecitabine + Tislelizumab
Induction with MRG003 and Tislelizumab followed by maintenance with Capecitabine and Tislelizumab
03
Who it enrols
Patients aged 18-70 with locally recurrent nasopharyngeal carcinoma >1 year after initial radical treatment, ECOG 0-1, and no prior systemic therapy for the recurrence. Excludes patients with active HBV/HCV, HIV, or severe prior immunotherapy toxicities.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Overall Survival
Duration of Response
Disease Control Rate
Beyond the preview
Go deeper on NCT07331428.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331428.